Group 1: Iodine Resource Distribution and Applications - The global iodine industry shows a clear regional distribution, with major production concentrated in Chile, Japan, and the United States. Chile is the largest iodine producer due to its unique nitrate mineral resources [2] - Iodine and iodides serve as essential functional raw materials across various industries, including pharmaceuticals, electronics, and chemicals. In the pharmaceutical sector, iodides are crucial for producing contrast agents, disinfectants, and antibiotics [3] Group 2: Company Development Plans - The company aims to integrate its main business with resource utilization, focusing on "technological innovation and green development" as strategic goals. It emphasizes collaborative innovation between industry and academia to reduce costs and enhance efficiency [3] - Future plans include increasing investment in technology research and development, particularly in the fine chemical sector, with a focus on pharmaceuticals. The company seeks to leverage opportunities from the new development pattern of domestic and international dual circulation [3]

Core Viewpoint - The company has completed the absorption and merger of Weifang Rongyuan, which has been officially deregistered, and this will not have a substantial impact on the company's consolidated financial statements or operational performance [1] Group 1 - The company received a deregistration notice from the Shouguang Administrative Approval Service Bureau on July 2, 2025, regarding Weifang Rongyuan [1] - The deregistration procedures for Weifang Rongyuan have been completed, and all assets, debts, business operations, personnel, and related qualifications have been inherited by the company [1] - The consolidation scope of the company's financial statements will change accordingly, but it will not have a significant impact on the company's financial and operational situation [1]

证券代码：301617 证券简称：博苑股份 公告编号：2025-034 山东博苑医药化学股份有限公司 关于完成吸收合并全资子公司的公告 2025 年 7 月 2 日，公司收到寿光市行政审批服务局下发的关于潍坊荣源《准 予注销登记通知书》，潍坊荣源工商注销登记手续已办理完毕。至此潍坊荣源依 法注销，本次吸收合并事项已完成，潍坊荣源全部资产、债权债务、业务、人员 和相关资质等均已由博苑股份承继，公司合并报表范围将发生相应变化，但不会 对公司合并报表产生实质性影响，不会对公司的财务及经营情况产生重大影响。 三、备查文件 《准予注销登记通知书》。 特此公告。 山东博苑医药化学股份有限公司 董事会 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、吸收合并概述 山东博苑医药化学股份有限公司（以下简称"公司"或"博苑股份"）于 2025 年 3 月 21 日召开第二届董事会第八次会议、第二届监事会第六次会议，于 2025 年 4 月 7 日召开 2025 年第二次临时股东会，审议通过了《关于公司吸收合 并全资子公司的议案》，同意博苑股份吸收合并全资子公司潍坊荣源新材料有 ...

Summary of Key Points Core Viewpoint - The report highlights a significant decline in the number of shareholders for many companies listed on the ChiNext board, indicating a trend of shareholder concentration and potential market volatility [1][2]. Group 1: Shareholder Trends - A total of 246 ChiNext stocks reported their latest shareholder numbers as of June 20, with 141 stocks experiencing a decline in shareholder count compared to June 10, and 15 of these stocks saw a decrease of over 10% [1]. - The stock with the largest decline in shareholder count was Jieya Co., with a decrease of 22.08% to 8,867 shareholders, and a cumulative drop of 15.10% in stock price since the concentration began [1][2]. - Other notable declines include Boyuan Co. with a 20.64% drop to 14,248 shareholders and Qide New Materials with an 18.75% decrease to 7,823 shareholders [1][2]. Group 2: Market Performance - Among the stocks with concentrated shareholding, the average increase since June 11 is 0.92%, with top performers including Haitai Technology, Boshuo Technology, and Hengshuai Co., which saw increases of 24.92%, 21.58%, and 20.59% respectively [2]. - The industries with the most concentrated stocks include machinery, basic chemicals, and pharmaceutical biology, with 20, 14, and 13 stocks respectively [2]. Group 3: Leverage and Funding - As of June 25, 37 stocks with concentrated shareholding attracted leveraged funds, with notable increases in financing balances for Zhongying Electronics, Qide New Materials, and Haitai Technology, which grew by 88.45%, 75.53%, and 66.61% respectively [2].

Summary of Key Points Core Viewpoint - The report highlights a significant decline in the number of shareholders for many companies listed on the ChiNext board, indicating a trend of shareholder concentration and potential market implications for these stocks [1][2][3]. Group 1: Shareholder Changes - A total of 209 ChiNext stocks reported their latest shareholder numbers as of June 20, with 126 stocks experiencing a decline in shareholder count compared to June 10, and 11 of these stocks seeing a decrease of over 10% [1]. - The stock with the largest decline in shareholder count is Jieya Co., with a decrease of 22.08% to 8,867 shareholders, and a cumulative drop of 13.97% in stock price since the concentration began [1]. - Other notable declines include Boyuan Co. (20.64% decrease) and Qide New Materials (18.75% decrease) [1][2]. Group 2: Market Performance - Among the concentrated stocks, the average price increase since June 11 is 0.31%, with top performers including Haitai Technology (25.88% increase), Hengshuai Co. (20.28% increase), and Boshuo Technology (18.98% increase) [2]. - The industries with the most concentrated stocks include machinery, electrical equipment, and computers, with 18, 12, and 11 stocks respectively [2]. Group 3: Leverage and Funding - As of June 24, 33 concentrated stocks have attracted leveraged funds, with notable increases in financing balances for Zhongying Electronics (88.68%), Haitai Technology (69.45%), and Qide New Materials (63.07%) [2]. Group 4: Continuous Decline in Shareholder Numbers - Companies like Zhongjian Huaneng and Kema Technology have seen continuous declines in shareholder numbers for 15 and 10 periods respectively, with cumulative declines of 20.86% and 23.30% [2][3]. - The report indicates that 38 ChiNext stocks have shown a continuous decline in shareholder numbers for more than three periods, with some stocks experiencing declines for up to 15 periods [1].

证券代码：301617 证券简称：博苑股份 公告编号：2025-033 山东博苑医药化学股份有限公司 山东博苑医药化学股份有限公司（以下简称"公司"）分别于 2025 年 4 月 23 日、2025 年 5 月 15 日召开第二届董事会第九次会议和 2024 年年度股东会， 审议通过了《关于变更公司注册资本、修订<公司章程>并办理工商变更登记的议 案》，具体内容详见公司于 2025 年 4 月 25 日在中国证券监督管理委员会指定信 息披露网站巨潮资讯网（http://www.cninfo.com.cn）披露的《关于变更公司注 册资本、修订<公司章程>并办理工商变更登记的公告》（公告编号：2025-026）。 1、名 称：山东博苑医药化学股份有限公司 7、住 所：山东省寿光市侯镇海洋化工园区新海路与大九路路口北 200 米 8、经营范围：许可项目：危险化学品生产；危险废物经营；危险化学品经 营；饲料添加剂生产；食品添加剂生产；货物进出口；技术进出口；发电、输电、 关于完成工商变更登记并换发营业执照的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 2、统一 ...

Group 1 - The core viewpoint of the news is that Hongshang Asset has conducted research on a listed company, Boyuan Co., focusing on its increased R&D investment and technological innovation strategies [1] - Boyuan Co. plans to enhance its R&D capabilities by increasing investment and expanding its R&D team, particularly by attracting high-end technical talent [1] - The company’s main products include inorganic iodides such as potassium iodide, potassium iodate, sodium iodide, and hydrogen iodide, which are used in pharmaceuticals, pesticides, feed, and optoelectronic materials [1] Group 2 - Boyuan Co.'s organic iodide product, trimethyl iodide, is primarily used as a protecting group in organic synthesis, especially in the production of antibiotics [1] - The pricing of iodide products is mainly based on the market price of refined iodine, determined through negotiations with customers [1] - The company is working on a high-end organic iodine and bromine new materials project with an annual capacity of 4,100 tons, which includes products like methyl iodide and dimethyl iodide [1]

Group 1: Research and Development - The company's R&D expenses increased year-on-year due to a focus on enhancing independent R&D capabilities and increasing investment in technological innovation [2] - The company is expanding its R&D team and optimizing its structure to ensure a leading advantage in key technologies [2] Group 2: Product Applications - The main inorganic iodide products include potassium iodide, potassium iodate, sodium iodide, and hydrogen iodide, which are used in pharmaceuticals, pesticides, feed, and optoelectronic materials [2] - The organic iodide product trimethyl iodide is primarily used as a protecting group in organic synthesis, particularly in the production of antibiotics [2] Group 3: Pricing Strategy - The pricing of iodide products is mainly based on the market price of refined iodine and is determined through negotiations with customers [3] Group 4: Production Capacity - The high-end organic iodine and bromine new materials project has an annual production capacity of 4,100 tons [3]

Summary of Key Points Core Viewpoint - Shandong Boyuan Pharmaceutical Chemical Co., Ltd. has successfully completed its initial public offering (IPO) of 25.7 million shares, with the shares set to be listed on the Shenzhen Stock Exchange on December 11, 2024. The total share capital post-IPO will be 102.8 million shares, with a significant portion subject to trading restrictions [1]. Group 1: IPO and Share Structure - The company received approval from the China Securities Regulatory Commission for its IPO, issuing 25.7 million shares, increasing the total share capital from 77.1 million to 102.8 million shares [1]. - After the IPO, 76.29% of the total shares will be subject to trading restrictions, while 23.71% will be freely tradable [1]. - Following a profit distribution plan approved at the 2024 annual shareholders' meeting, the total share capital will further increase to 133.64 million shares, with 76.29% still under trading restrictions [1]. Group 2: Lock-up Period and Compliance - Under the IPO terms, 10% of the shares allocated to offline investors will be subject to a 6-month lock-up period, while 90% will be tradable immediately upon listing [2]. - All shareholders holding restricted shares have complied with the lock-up commitments, and there are no violations affecting the listing of these shares [2]. Group 3: Changes in Share Capital Structure - The number of restricted shares decreased by 1,724,702 shares, resulting in 100,230,000 restricted shares, which is 75% of the total share capital post-IPO [4]. - The number of unrestricted shares increased to 33,410,000, representing 25% of the total share capital after the release of the lock-up [4]. Group 4: Sponsor's Verification - The sponsor has confirmed that the release of restricted shares complies with relevant regulations and that the company's disclosures regarding the restricted shares are accurate and complete [6].

中泰证券股份有限公司 关于山东博苑医药化学股份有限公司 首次公开发行网下配售限售股上市流通的核查意见 中泰证券股份有限公司（以下简称"中泰证券"或"保荐人"）作为山东博苑医 药化学股份有限公司（以下简称"博苑股份"、"公司"）首次公开发行股票并在创 业板上市的保荐人履行持续督导职责，根据《证券发行上市保荐业务管理办法》 《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作》《深圳证券交易所上市公司自律监管指 引第 13 号——保荐业务》等有关规定，对博苑股份首次公开发行网下配售限售 股上市流通事项进行了核查，核查意见如下： 一、首次公开发行网下配售股份概况 根据中国证券监督管理委员会《关于同意山东博苑医药化学股份有限公司首 次公开发行股票注册的批复》（证监许可[2024]1415 号），公司首次公开发行人民 币普通股（A 股）股票 2,570 万股，并于 2024 年 12 月 11 日在深圳证券交易所 创业板上市。公司首次公开发行股票前总股本为 7,710 万股，首次公开发行股票 完成后公司总股本为 10,280 万股，其中有流通限制或限售安排的股份 ...